druglinker conjugates for adc

Deruxtecan 是一种 ADC 药物-接头偶联物，由 DX-8951 (DXd) 的衍生物和马来酰亚胺-GGFG 肽接头组成，用于合成 DS-8201 和 U3-1402。

ABBV-969 Payload (Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT) 是一种药物-连接子偶联物，用于抗体药物偶联物（ADCs）合成。该载荷含有拓扑异构酶 I 抑制剂分子及化学连接子，可与抗 c-Met 抗体偶联，从而生成具有靶向抗癌活性的 ABBV-969 ADCs。

CL2-SN-38, a part of the antibody-drug conjugate (ADC), can conjugate with the anti-Trop-2-humanized antibody hRS7. SN-38 is an inhibitor of DNA topoisomerase I.

Mc-doxhzn is a protein-binding prodrug of DOXUbicin (DNA topoisomerase II inhibitor) with acid sensitivity.

Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) 是一种靶向人表皮生长因子受体2 (HER2) 的 ADC，作为 T-DM1 的活性代谢产物含有微管蛋白聚合抑制剂 DM1，可抑制微管蛋白聚合，常用于乳腺癌的研究。

Vipivotide tetraxetan (PSMA-617) 是一种高效的前列腺特异性膜抗原抑制剂，其Ki 值为 0.37 nM。

Doxorubicin-SMCC is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

MC-GGFG-DX8951(MC-GGFG-Exatecan)是一种抗体偶联药物（ADC）的药物-连接子偶联物（drug-linker conjugate）.由强效的DNA拓扑异构酶I抑制剂DX8951、连接子MC和可被蛋白酶降解（cleavable）的肽链GGFG组成，具有抗肿瘤的潜力。

MC-Val-Ala-PBD is a drug-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala[1].

McMMAF 是一种保护基团共轭的 MMAF。它是一种具有马来酰亚胺基己酰基接头（MC 接头）的 MMAF 衍生物， MMAF 是一种有效的微管蛋白聚合抑制剂。它可与抗体或其他蛋白质或生物聚合物结合。

SMCC-DM1 是一种药物-接头偶联物，由有效的微管破坏剂 DM1 和接头 SMCC 组成，用于制备抗体药物偶联物。

7-O-(Amino-PEG4)-paclitaxel is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

7-O-(Cbz-N-amido-PEG4)-paclitaxel is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for antibody-drug conjugates (ADCs) that combines the ADC linker (Acetylene-linker-Val-Cit-PABC) with the potent tubulin inhibitor MMAE.

AcLys-PABC-VC-Aur0101 is a drug-linker conjugate for anti-CXCR4 ADC with potent antitumor activity, comprising the auristatin microtubule inhibitor Aur0101, connected through the cleavable linker AcLys-PABC-VC[1].

Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable tetraethylene glycol (4 unit PEG) antibody-drug conjugate (ADC) linker employed in the synthesis of ADCs[1].

AmPEG6C2-Aur0131 is a drug-linker conjugate designed for anti-CXCR4 ADC applications, showcasing potent antitumor activity. It incorporates Aur0131, an auristatin-based microtubule inhibitor, connected through the non-cleavable AmPEG6C2 linker.

CCK2R Ligand-Linker Conjugate 1 is a hydrophilic peptide linker that conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) as ligand-linker conjugates[1].

CL2A-SN-38 由CL2A链接子和抗癌化合物SN-38 组成，可在肿瘤细胞内和肿瘤微环境中递送活性活性分子，通常会与抗体制成具有生物活性的抗体偶联活性分子 (ADC)。

Cys-mcMMAD is a drug-linker conjugate for ADC (antibody-drug conjugate) featuring MMAD, a potent tubulin inhibitor.

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2. MMAE, a potent tubulin inhibitor, serves as the cytotoxic component in this formulation.

DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate that combines the microtubulin inhibitor DM1 (mertansine), which is an antibody-conjugatable maytansinoid designed to reduce systemic toxicity and improve tumor-specific delivery, with the linker DBCO-PEG4-Ahx, for the development of antibody drug conjugates (ADCs).

DBCO-PEG4-VA-PBD is a cleavable 4-unit PEG ADC linker utilized in antibody-drug conjugate (ADC) synthesis [1].

DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for antibody-drug conjugates (ADC), comprises the ADC linker DBCO-PEG4-VC-PAB and the potent ADC cytotoxin DMEA-PNU-159682. The cytotoxin includes metabolites of nemorubicin (MMDX) from liver microsomes and the ADC cytotoxin PNU-159682[1].